Knox Henderson interviews Hugh Rogers on XPhyto’s saliva based rapid screening test
In a recent InvestorIntel interview Knox Henderson speaks with Hugh Rogers , CEO and Director, of XPhyto Therapeutics Corp. (CSE: XPHY | OTCQB: XPHYF) about their rapid COVID-19 screening test and RT-PCR test for point-of-care COVID-19 saliva detection tests. “Rapid test takes less than 5 minutes, it is disposable, it is low cost.” Hugh said. “PCR on other hand is a laboratory technique that requires equipment.”
In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Hugh went on to say that XPhyto is focused on the kit to be used with a PCR machine, particularly focused on pocket PCRs which are smaller portable versions of much larger laboratory equipment. “We have developed a platform for COVID-19 testing using proprietary RNA probes and these can be used in both rapid test and a PCR kit.” Hugh added. To watch the full interview, click here
About XPhyto Therapeutics Corp.
XPhyto Therapeutics Corp. is accelerating the next-generation drug delivery, diagnostic, and phytochemical investment opportunities: precision transdermal and oral dissolvable drug dosage forms; rapid, low-cost infectious disease and oral health screening tools; and validation of approved cannabinoid-based therapeutics focused on European markets. To learn more about XPhyto Therapeutics Corp., click here
Disclaimer: XPhyto Therapeutics Corp. is an advertorial member of InvestorIntel Corp.
Raj Shah has professional experience working for over a half a dozen years at financial firms such as Merrill Lynch and First Allied Securities Inc., ... <Read more about Raj Shah>